News from decision resources group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 17, 2014, 15:00 ET
Decision Resources Group Logo

Latin American Electrophysiology Mapping and Ablation Device Market Will Reach Nearly $90 Million by 2023

 Decision Resources Group finds that the Latin American electrophysiology (EP) mapping and ablation device market will grow moderately through...

Dec 17, 2014, 12:34 ET
Decision Resources Group Logo.

U.S. And European Markets for Craniomaxillofacial Devices Will Grow Through 2023 Despite Pricing Pressures

 Decision Resources Group finds that the market for craniomaxillofacial (CMF) devices in the United States and Europe will grow through 2023....

Dec 03, 2014, 13:00 ET
Decision Resources Group Logo.

PCSK9 and CETP Inhibitors Are Set to Transform the Dyslipidemia Market

Decision Resources Group finds that the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and cholesteryl ester transfer...

Dec 02, 2014, 11:00 ET
Logo

The Type 2 Diabetes Population will Continue to Expand in China, But Patient Access to Novel Non-Insulin Treatments is Sub-Optimal

Decision Resources Group finds that, for the treatment of type 2 diabetes in China, patient access to premium-priced agents is impeded as not...

Dec 01, 2014, 13:46 ET
Decision Resources Group Logo

Based on a Review of 1,000 CKD-ND Patients' Charts, Nephrologists Often Under- or Over-Estimate their Use of Key Renal Medications

 Decision Resources Group finds that, based on a review of 1,000 charts for chronic kidney disease non-dialysis (CKD-ND) patients, audited...

Nov 24, 2014, 13:30 ET
Decision Resources Group Logo.

U.S. Claims Data Show That Biogen Idec's Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients

 Decision Resources Group finds that, according to U.S. patient-level claims data, Biogen Idec's Tecfidera, the third-to-market oral disease...

Nov 24, 2014, 11:03 ET
Decision Resources Group Logo

Surveyed European Oncologists Indicate that Predictive Biomarkers that Identify Patients Most Likely to Respond to Therapies Are a Clear Advantage for Costly Oncology Drugs

Decision Resources Group finds that biomarker driven prescribing is likely to positively influence perceptions of oncology drugs for both...

Nov 20, 2014, 13:31 ET
Decision Resources Group Logo

Allergan's Semprana and CoLucid's Lasmiditan, Two Novel Acute Migraine Therapies, Will Drive Market Growth Through 2023

 Decision Resources Group finds that the overall migraine market will grow from approximately $3 billion in 2013 to over $5 billion in 2023 in...

Nov 20, 2014, 11:30 ET
Decision Resources Group Logo.

European Interventional Cardiology Device Revenues Declined in 2014 Due to Price Erosion

Decision Resources Group finds that the European interventional cardiology (IC) device market will continue to be strongly limited by price...

Nov 20, 2014, 11:00 ET
Decision Resources Group Logo.

Adoption of Novel Interventional Oncology Devices Will Be Slow in Europe Until the Economy Recovers

 Decision Resources Group finds that the European interventional oncology device market is less penetrated, relative to the market in the...

Nov 20, 2014, 10:12 ET
Decision Resources Group Logo

Hospitals Form Alliances in Detour from Last Year's Blockbuster Mergers and Acquisitions

 Decision Resources Group finds that Affordable Care Act (ACA)-driven consolidation in the hospital sector has evolved from the...

Nov 19, 2014, 11:45 ET
Decision Resources Group Logo

The First Class of Biosimilars to Enter the U.S. Market Will Generate $1.8 Billion by 2023

 Decision Resources Group finds that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim, which is...

Nov 18, 2014, 11:00 ET
Decision Resources Group Logo.

Zytiga is Currently the Most Commonly Prescribed Second-Line Therapy for Metastatic Castrate-Resistant Prostate Cancer, According to Surveyed European Oncologists

 Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for...

Nov 12, 2014, 12:00 ET
Decision Resources Group Logo

Medtronic and St. Jude Medical Dominate the European Pain Management Device Market

 Decision Resources Group finds that the European pain management device market generates a majority of revenue from select products, such as...

Nov 12, 2014, 11:00 ET
Decision Resources Group Logo.

The Ulcerative Colitis Market Will Grow Over the Next Decade, Reaching $4.2 Billion in 2023

Decision Resources Group finds that the ulcerative colitis (UC) market will grow over the next decade from $2.7 billion in 2013 to $4.2 billion in...

Nov 12, 2014, 10:00 ET
Decision Resources Group Logo

Launch of Novel Oral HIF-PH Inhibitors Will Intensify the Competition for Renal Anemia Patient Share

 Decision Resources Group finds that surveyed nephrologists expect hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHi) to capture...

Nov 11, 2014, 14:00 ET
Decision Resources Group Logo.

Surveyed Endocrinologists in Europe and the United States Only Expect to Switch a Minority of Their Patients Currently Receiving Lantus to Biosimilar Insulin Glargine

Decision Resources Group finds that surveyed endocrinologists in the United States, France and Germany expect to switch less than one-third of...

Nov 11, 2014, 10:00 ET
Decision Resources Group Logo

U.S. Healthcare Reform Presents Challenges to the Diagnostic Imaging System Market, Resulting in Only Modest Growth Through 2023

 Decision Resources Group finds that the diagnostic imaging system market in the United States is being hindered by ongoing healthcare reform...

Nov 06, 2014, 11:00 ET
Decision Resources Group Logo.

Surveyed U.S. Specialists Perceive Gilead's Harvoni, the First Single-Tablet Regimen for Hepatitis C Virus Infections, As Having Key Advantages Over Emerging Treatment Options

Decision Resources Group finds that surveyed specialists anticipate prescribing Gilead's Harvoni to a high proportion of their genotype-1 infected...

Nov 06, 2014, 10:00 ET
Decision Resources Group Logo

U.S. Minimally Invasive Spine Technology Market To Grow at Almost 6 Percent Annually Through 2023, Much Faster than the Traditional Open Spinal Implant Market

 Decision Resources Group finds that the United States minimally invasive spine technology market will grow at approximately 6 percent annually...